Engineering Soluble GPCRs for Antibody Drug Discovery
8:30 am - Wednesday 3rd February 2027
- GPCRs are challenging membrane targets to express and purify for antibody drug discovery
- Generative AI can reengineer GPCRs into soluble formats ready for drug discovery
- This technology enables antibody discovery against Amylin Receptor, a next-generation obesity target
